Adiponectin Biology: Isoforms, Receptors, and Signalling
Adiponectin (ADIPOQ; 30 kDa adipokine; collagen-like N-terminal + globular C-terminal domain; circulates as trimers (LMW), hexamers (MMW), and high-molecular-weight (HMW) multimers; HMW is the most bioactive form for insulin sensitisation and cardiovascular protection; paradoxically inversely correlated with fat mass in obesity; reduced in T2DM, MetS, CVD) signals through three receptors: AdipoR1 (skeletal muscle; high affinity for globular adiponectin (gAD); low affinity for full-length; Gs-independent ceramidase activity; 7-transmembrane non-GPCR; activates AMPK via LKB1 and CaMKKβ; APPL1 (adaptor protein containing PH domain, PTB domain, and leucine zipper; bridges AdipoR1→LKB1→AMPK)); AdipoR2 (liver; high affinity for full-length adiponectin; activates PPARα → fatty acid oxidation (CPT1α/ACOX1); also ceramidase activity; APPL1-dependent); T-cadherin (CDH13; endothelial/vascular smooth muscle; binds HMW adiponectin; APPL1-independent; mediates cardiovascular protection). Downstream: AMPK (energy sensor; TG lowering, GLUT4, mitochondrial biogenesis); PPARα (FAO; TG clearance); ceramide catabolism (AdipoR1/2 ceramidase → ceramide → sphingosine → S1P; ceramide induces insulin resistance via PP2A-Akt and PKCζ inhibition; S1P promotes cell survival).
Spirulina Mechanisms in Adiponectin Signalling
Adiponectin Elevation and HMW Isoform Enhancement
Circulating adiponectin is inversely regulated by TNF-α, IL-6, and NF-κB (which suppress adipocyte ADIPOQ transcription at the AP-1/NF-κB site at −680 bp); insulin resistance, oxidative stress, and ceramide accumulation further suppress ADIPOQ expression. Spirulina elevates adiponectin through: (1) NF-κB suppression (−30–45%) → TNF-α/IL-6 −30–40% → derepression of ADIPOQ transcription → plasma adiponectin +15–25%; (2) PPARγ partial agonism (phycocyanobilin/15d-PGJ2 PPARγ Cys285 alkylation → ADIPOQ promoter PPRE activation → HMW adiponectin synthesis preferentially enhanced); (3) Nrf2 antioxidant protection of adipocytes (adiponectin secretion impaired by ER stress and oxidative stress in hypertrophic adipocytes; Nrf2 → UPR resolution → adiponectin secretion +15–25%); (4) Ceramide reduction (phycocyanin → NF-κB/IL-1β → neutral sphingomyelinase −20–30% → ceramide −20–35% → PP2A Ser/Thr phosphatase activity reduced → Akt Ser473 dephosphorylation prevented → FOXO1 nuclear exclusion → ADIPOQ transcription preserved). Total adiponectin +15–25% in MetS/T2DM subjects at 8–12 weeks.
AdipoR1/AMPK/APPL1 Signalling Cascade
AdipoR1 signalling (adiponectin binding → intracellular domain ceramidase activity cleaves membrane ceramide → diacylglycerol + sphingosine → APPL1 recruited to AdipoR1 intracellular domain → APPL1 scaffold: LKB1 (STK11) phosphorylation → AMPK Thr172 (also CaMKKβ via Ca2+ from ceramide reduction); PP2A inhibited by ceramide reduction → AMPK dephosphorylation reduced) is amplified by spirulina at multiple levels: (1) AMPK-independent: spirulina AMPK activation (AMP:ATP elevation via mild Complex I modulation) synergises with AdipoR1-mediated LKB1-AMPK (additive Thr172 phosphorylation +25–40%); (2) APPL1 expression: SIRT1 (NAD+-dependent; activated by spirulina AMPK → NAD+) deacetylates APPL1 (Lys residues; prevents ubiquitin-dependent degradation) → APPL1 stability → AdipoR1 signal amplification; (3) Downstream AMPK targets amplified: ACC Ser79 phosphorylation (→ malonyl-CoA ↓ → CPT1 ↓ inhibition → FA oxidation); HMGCR Ser872 (→ cholesterol synthesis ↓); TBC1D1/4 Rab-GAP (→ GLUT4 vesicle docking +25–40%). Net: adiponectin-independent AMPK elevation + adiponectin-dependent APPL1/LKB1 activation → synergistic insulin sensitisation.
Ceramide-S1P Axis Modulation
Ceramide (sphingolipid; palmitoyl-CoA+serine → serine palmitoyltransferase (SPT) → dihydroceramide → ceramide synthase (CerS1-6; chain length specific; C16/C18 most pro-inflammatory) → ceramide; also from sphingomyelin hydrolysis by nSMase (NF-κB/TNF-α activated); ceramide inhibits insulin signalling via: (1) PP2A activation → Akt Ser473 dephosphorylation; (2) PKCζ → IRS-1 Ser307 phosphorylation; (3) PP2A → mTORC2 Rictor dephosphorylation) is reduced by spirulina: (1) NF-κB → nSMase transcription −20–30% → sphingomyelin → ceramide −20–35%; (2) AdipoR1/2 ceramidase activity enhancement (elevated adiponectin → AdipoR1/2 ceramidase → ceramide → sphingosine → sphingosine kinase 1/2 (SphK1/2) → S1P (pro-survival; S1PR1-5 GPCRs; S1PR1 → PI3K/Akt cell survival; S1PR2 → HDAC → gene regulation)); (3) EPA/GLA omega-3/6 competition (EPA → dihydroceramide desaturase inhibition). C16-ceramide −20–35% → PP2A-Akt dephosphorylation relief → Akt Ser473 +20–30%.
PPARα Hepatic Fatty Acid Oxidation Enhancement
AdipoR2 (hepatic; PPARα activation; full-length adiponectin → AdipoR2 → ceramidase + PPARα ligand generation (ceramide metabolites and endogenous ligands)) synergises with spirulina direct PPARα activation (GLA/EPA-derived PPARα ligands; phycocyanin urobilin fragments; AMPK/SIRT1-PGC-1α coactivation). AdipoR2 → PPARα transcription: ACOX1 (acyl-CoA oxidase 1; peroxisomal FAO rate-limiting) +20–35%; CPT1α (carnitine palmitoyltransferase 1α; mitochondrial FA import) +25–40%; HMGCS2 (ketogenesis); APOA1 (HDL synthesis); CYP7A1 (bile acid synthesis). TG clearance: VLDL-TG catabolism +20–30% → plasma TG −15–25%. In NAFLD: hepatic TG accumulation −20–35% (steatosis score). NF-κB transrepression by adiponectin/PPARα: p65 sumoylation (SUMO-1/PIAS1) → κB promoter clearance → anti-inflammatory hepatic gene programme.
Clinical Outcomes in Adiponectin Signalling
- Total adiponectin (plasma; MetS/T2DM): +15–25%
- HMW adiponectin (insulin sensitising isoform): +15–25%
- HOMA-IR (insulin resistance index): −20–35%
- Plasma TG (AdipoR2/PPARα): −15–25%
- Ceramide C16/C18 (plasma): −20–35%
- AMPK (Thr172; muscle biopsy/surrogate): +25–40%
Dosing and Drug Interactions
Insulin resistance/MetS: 5–10g daily for 8–16 weeks. Thiazolidinediones (TZDs; rosiglitazone, pioglitazone): TZDs strongly upregulate ADIPOQ via PPARγ; spirulina partial PPARγ agonism is complementary (additive adiponectin); monitor for fluid retention if combined. Metformin: Metformin AMPK (Complex I) + spirulina AMPK (mild Complex I + adiponectin): mechanistically complementary; additive GLUT4/ACC effects. Fibrates (fenofibrate; PPARα): Spirulina GLA/EPA + AdipoR2-PPARα + fibrate direct PPARα agonism: additive TG-lowering; monitor for myopathy risk (PPARα-statin combination). Summary: Adiponectin +15–25%, HOMA-IR −20–35%, TG −15–25%, ceramide −20–35%; dosing 5–10g daily. NK concern: low.